MediWound (NASDAQ:MDWD – Get Rating) and Mind Medicine (MindMed) (NASDAQ:MNMD – Get Rating) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, analyst recommendations, risk, profitability and earnings.
This is a breakdown of recent recommendations and price targets for MediWound and Mind Medicine (MindMed), as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Mind Medicine (MindMed)||0||0||2||0||3.00|
MediWound presently has a consensus price target of $7.13, suggesting a potential upside of 285.14%. Mind Medicine (MindMed) has a consensus price target of 7.00, suggesting a potential upside of 1,035.07%. Given Mind Medicine (MindMed)’s higher possible upside, analysts clearly believe Mind Medicine (MindMed) is more favorable than MediWound.
Earnings & Valuation
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|MediWound||$23.76 million||2.58||-$13.55 million||($0.51)||-3.63|
|Mind Medicine (MindMed)||N/A||N/A||-$93.04 million||-0.23||-2.68|
MediWound has higher revenue and earnings than Mind Medicine (MindMed). MediWound is trading at a lower price-to-earnings ratio than Mind Medicine (MindMed), indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
13.6% of MediWound shares are held by institutional investors. Comparatively, 12.4% of Mind Medicine (MindMed) shares are held by institutional investors. 2.1% of Mind Medicine (MindMed) shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
This table compares MediWound and Mind Medicine (MindMed)’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Mind Medicine (MindMed)||N/A||-62.00%||-57.05%|
Volatility and Risk
MediWound has a beta of 1.04, meaning that its share price is 4% more volatile than the S&P 500. Comparatively, Mind Medicine (MindMed) has a beta of 1.55, meaning that its share price is 55% more volatile than the S&P 500.
Mind Medicine (MindMed) beats MediWound on 8 of the 12 factors compared between the two stocks.
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.
About Mind Medicine (MindMed)
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company is headquartered in Vancouver, Canada.
Receive News & Ratings for MediWound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediWound and related companies with MarketBeat.com's FREE daily email newsletter.